Cafepharma Today

May 22 2025 - Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Medivation Earnings Call Nuggets: Gross to Net Conversion and the Pre-Chemo Market
Wall Street Cheat Street
Sunday, March 3, 2013 - 11:20am
tags:
Medivation, earnings
Are Short Sellers Right About Spectrum?
Motley Fool
Sunday, March 3, 2013 - 11:19am
tags:
Spectrum Pharmaceuticals
3 Bio-Pharmaceuticals Insiders Love
Motley Fool
Sunday, March 3, 2013 - 11:19am
tags:
MannKind, Merrimack Pharmaceuticals, Tesaro
Cellceutix - A Biotech To Consider For 2013
Seeking Alpha
Sunday, March 3, 2013 - 11:18am
tags:
Cellceutix
Who's the Frailest Big Pharma of All?
Motley Fool
Saturday, March 2, 2013 - 4:08pm
tags:
Bristol-Myers Squibb, AstraZeneca, Pfizer, Eli Lilly, Sanofi
Vertex Enters Critical Phase (video)
Motley Fool
Saturday, March 2, 2013 - 4:04pm
tags:
Vertex Pharmaceuticals
Mylan Just Got More Interesting
Motley Fool
Saturday, March 2, 2013 - 4:03pm
tags:
Mylan
KYTHERA Biopharmaceuticals, Inc. to Present New Data at 2013 American Academy of Dermatology (AAD) Annual Meeting Demonstrating Results for ATX-101 in the Reduction of Submental Fat (SMF) or “Double Chin”
Yahoo/BusinessWire
Saturday, March 2, 2013 - 4:03pm
tags:
ATX-101, obesity, weight loss, Kythera Biopharmaceuticals
Assessing The Dividend Growth Potential For The New Abbott
Seeking Alpha
Saturday, March 2, 2013 - 4:01pm
tags:
Abbott Laboratories
How Serious Is This News for Diabetes Drugmakers?
Motley Fool
Saturday, March 2, 2013 - 4:00pm
tags:
pancreatitis, diabetes, type 2 diabetes, Merck, AstraZeneca, Bristol-Myers Squibb
PDL BioPharma's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Seeking Alpha
Saturday, March 2, 2013 - 3:57pm
tags:
PDL Biopharma, earnings
1 Overblown Biotech Selloff
Motley Fool
Saturday, March 2, 2013 - 3:57pm
tags:
Medivation
German Institute for Quality and Efficiency in Health Care (IQWiG) Publishes Dossier Evaluation within Early Benefit Assessment Process of Pixuvri (pixantrone)
Yahoo/PR Newswire
Saturday, March 2, 2013 - 3:56pm
tags:
Pixuvri, non-Hodgkin B-cell lymphoma, non-Hodgkin's lymphoma, Cell Therapeutics
3 Humongous Health-Care Stocks This Week
Motley Fool
Saturday, March 2, 2013 - 3:54pm
tags:
Clovis Oncology, Orexigen, Optimer Pharmaceuticals
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
Yahoo/PR Newswire
Saturday, March 2, 2013 - 3:53pm
tags:
Affymax
Sequestration puts speed bumps in drug review fast lane
Fierce Pharma
Friday, March 1, 2013 - 12:00pm
tags:
drug reviews, FDA, sequesters
FDA halts pediatric study of Amgen's Sensipar after death
Fierce Pharma
Friday, March 1, 2013 - 12:00pm
tags:
Sensipar, Amgen, FDA, clinical trials, hyperparathyroidism
Novavax Earnings: Here’s Why Investors are Selling Shares Now
Wall St. Cheat Sheet
Friday, March 1, 2013 - 11:58am
tags:
Novavax, earnings
Idenix Reports In-Line 4Q Loss
Yahoo/Zacks
Friday, March 1, 2013 - 11:47am
tags:
earnings, Idenix
Let the sunshine in: New efforts to reveal the ties between doctors and drug firms
The Economist
Friday, March 1, 2013 - 11:46am
tags:
Physician Payment Sunshine Act, physicians

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.